Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

Primary care physicians aren’t quick to diagnose lymphedema in patients with obesity, a situation that needs to change, ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Consuming certain spices, such as chili pepper, turmeric, ginger, and cinnamon, may positively affect metabolism and help ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Popular GLP-1 weight loss drugs like Ozempic and Zepbound may help lower a woman’s risk for 14 types of cancer, a new study ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.